Definium Therapeutics announced that its LSD therapy met its primary endpoint in a Phase 3 trial for major depressive disorder, marking a significant milestone for psychedelic-assisted treatment. The study, the first Phase 3 trial for the drug candidate, showed statistically significant improvement in depression symptoms compared to placebo.
The positive data brings Definium's LSD therapy closer to potential approval by regulators, a step that could reshape the treatment landscape for major depression. Psychedelic compounds have gained renewed scientific interest in recent years as alternatives to conventional antidepressants, which often carry side effects and delayed onset of action.
According to Definium, the trial enrolled patients with moderate to severe major depressive disorder. The company did not disclose specific numerical results in the announcement, citing plans to present full data at an upcoming medical conference. Definium said it expects to meet with regulators to discuss next steps toward a New Drug Application.
The results add to a growing body of evidence supporting psychedelics as therapeutic tools. If approved, Definium's LSD therapy would compete with other psychedelic candidates, including MDMA and psilocybin, that are also advancing through late-stage development for psychiatric conditions.
Some researchers caution that long-term safety data remains limited and that the subjective effects of LSD may pose challenges in clinical settings. Definium acknowledged that larger studies are needed to confirm durability of response.